NEW YORK, NY / ACCESSWIRE / February 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a
class action lawsuit has been filed against Tyme Technologies, Inc. ("Tyme" or the "Company") (NASDAQ: TYME) and certain of its
officers, on behalf of shareholders who purchased or otherwise acquired Tyme securities between March 14, 2018 and January 18,
2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:
www.bgandg.com/tyme.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the
Securities Exchange Act of 1934.
The Complaint alleges that Defendants made materially false and misleading statementsand/or failed to disclose that: (1) Tyme
had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (2) Tyme
had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (3) the omission of an
appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (4) as a
result, Tyme's public statements were materially false and misleading at all relevant times.
On January 18, 2019, Tyme reported results from an open-label Phase 2 clinical trial evaluating the Company's product candidate
SM-88 in patients with end-stage pancreatic cancer. Although Tyme characterized the results as positive, stating that SM-88
"improves survival," the trial did not include a control group, and Tyme's announcement merely compared survival data to historical
controls. On this news, Tyme's stock price fell $1.32 per share, or 35.39%, to close at $2.41 per share on January 18, 2019.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site:
www.bgandg.com/tyme or you may contact Peretz Bronstein, Esq. or his Investor Relations
Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Tyme you have until March
29, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you
serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action
security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
